Pharmacokinetics of tin‐mesoporphyrin in man and the effects of tin‐chelated porphyrins on hyperexcretion of heme pathway precursors in patients with acute inducible porphyria
Richard A. Galbraith, Attallah Kappas – 1 June 1989 – Tin‐mesoporphyrin shares many of the properties of its parent compound, tin‐protoporphyrin. These include competitive inhibition of heme oxygenase, amelioration of jaundice and suppression of chemically induced hepatic porphyria. Tin‐mesoporphyrin is cleared from the plasma of normal subjects with dose‐dependent pharmacokinetics (T1/2 = 3.8 hr following i.v. administration of 1 μmole per kg body weight), and small amounts (<1% of administered dose) are excreted into the urine and feces.